

KURZPROTOKOLL
20150136

Öffentlicher Titel	Beobachtungsstudie zu Blinatumomab bei B-ALL
Wissenschaftl. Titel	An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices
Kurztitel	20150136
Studienart	multizentrisch, Anwendungsbeobachtung, prospektiv, offen/unverblindet, einarmig, nicht-interventionelle Studie
Studienphase	nicht zutreffend
Erkrankung	Blut: Akute lymphatische Leukämie (ALL): Rezidiert/refraktär
Einschlusskriterien	- Medical records of patients initiating Blincyto after country-specific reimbursement in routine clinical practice will be eligible for abstraction.
Ausschlusskriterien	- Medical records of patients who have participated in Blincyto clinical trials will be excluded since their treatment will be prescribed by the study protocol unless the patient is receiving new Blincyto treatment outside the clinical trial. - Medical records of patients participating in other Amgen non-interventional prospective studies in which safety endpoints are collected will be excluded - Medical records of patients who have received Blincyto via an expanded access/compassionate use program will be excluded - In countries where patient informed consent is required for access to their medical records, any patient who does not provide informed consent will be excluded.
Alter	18 Jahre und älter
Prüfzentren	Universitätsmedizin Frankfurt (Nachbeobachtung) Medizinische Klinik II, Hämatologie/Onkologie Theodor-Stern-Kai 7 60590 Frankfurt am Main Roswitha Kotthoff Tel: 069 6301-87146 Fax: 069 6301-7463 r.kotthoff@med.uni-frankfurt.de
Sponsor	AMGEN GmbH
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT03117621
Links	Studiendokumente zum Download (roXtra)